My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

AIM ImmunoTech Inc. Common Stock (NY:AIM)

1.370 -0.080 (-5.52%)

Official Closing Price Updated: 8:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AIM ImmunoTech Inc. Common Stock

< Previous 1 2 3 4 5 6 Next >

FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer ↗

March 16, 2022

Via Benzinga

AIM ImmunoTech Shares Encouraging Data From Ampligen Study In Pancreatic Cancer ↗

March 09, 2022

AIM ImmunoTech Inc (NYSE: AIM) announced the publication of positive data from a single-center named patient program treating advanced and metastatic pancreatic...

Via Benzinga

JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th

January 12, 2022

- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...

From JTC Team, LLC

Via AccessWire

Earnings Scheduled For November 11, 2021 ↗

November 11, 2021

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million. • Reshape...

Via Benzinga

AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses ↗

September 30, 2021

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis...

Via Benzinga

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease ↗

September 28, 2021

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two...

Via Benzinga

AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients ↗

September 21, 2021

AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive...

Via Benzinga

AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction ↗

September 08, 2021

AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential...

Via Benzinga

Earnings Scheduled For August 13, 2021 ↗

August 13, 2021

Companies Reporting Before The Bell • Jaguar Health (NASDAQ:JAGX) is expected to report quarterly loss at $0.03 per share on revenue of $7.28 million. • Fangdd...

Via Benzinga

Earnings Scheduled For May 14, 2021 ↗

May 14, 2021

Companies Reporting Before The Bell • Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report...

Via Benzinga

AIM ImmunoTech's Ampligen Shows Favorable Safety Profile In Early-Stage COVID-19 Study ↗

April 07, 2021

AIM ImmunoTech Inc (NYSE: AIM) has completed the dosing of Cohort 1 in Phase 1 study on the safety of Ampligen as an intranasal therapy, as potential...

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.